This is a type of cancer that starts in the cells that line glands. It's called 'clear cell' because the cancer cells look like they've been washed out, making them appear transparent under a microscope. It often develops in the female reproductive organs.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Clear Cell Adenocarcinoma?
Clear cell adenocarcinoma is a cancer that starts in gland-forming cells and is named for how those cells look under a microscope: many have pale, almost empty-looking interiors. It is defined by this cell type rather than by a single organ, and it occurs mostly in the female reproductive tract. The ovary is the most common site, where clear cell carcinoma accounts for roughly 1 in 10 epithelial ovarian cancers (the main group of ovarian cancers). It can also start in the lining of the uterus (the endometrium), the cervix or the vagina. The cell type matters because clear cell cancers behave differently from the more common cancers in the same organs. In the ovary, for example, clear cell carcinoma is usually found at an early stage, but once it has spread it tends to respond less well to standard chemotherapy than the most common ovarian cancer, high-grade serous carcinoma. Where the cancer started and how far it has spread shape the symptoms, the treatment and the outlook. In the ovary it often comes to attention as a pelvic mass or with bloating, pressure or pain, while in the uterus, cervix or vagina the usual first sign is abnormal vaginal bleeding. Clear cell cancer of the kidney is classified separately as clear cell renal cell carcinoma and is treated as a kidney cancer, so it is not the focus here.
Most clear cell adenocarcinomas have no single identifiable cause, and the known risk factors differ by site. In the ovary, the strongest link is endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus. About half of people with ovarian clear cell carcinoma also have endometriosis, and endometriosis is associated with roughly three times the usual risk of this cancer. That is an association, not a sign that endometriosis will turn into cancer in any one person. Inherited conditions also play a part. Lynch syndrome, an inherited condition that raises the risk of colon, uterine and ovarian cancers, is linked more often with clear cell and endometrioid ovarian cancers than with other types. Inherited changes in the BRCA1 and BRCA2 genes, which account for many hereditary ovarian cancers, are uncommon in the clear cell type. In the cervix and vagina, clear cell adenocarcinoma is linked to diethylstilbestrol (DES), a synthetic estrogen prescribed to some pregnant women between 1940 and 1971. People exposed before birth, often called DES daughters, have about 40 times the usual risk, yet the cancer stayed rare: about 1 in 1,000 DES daughters developed it. These cases peaked in the 1970s and are extremely rare now. Clear cell cancers of the cervix and vagina without DES exposure, like clear cell cancer of the uterine lining, usually occur after menopause.
Clear cell adenocarcinoma can only be confirmed by a pathologist examining tissue under a microscope. The sample may come from a biopsy, such as a small piece of the uterine lining or cervix taken in a clinic, or from surgery to remove an ovarian mass. The pathologist looks for the characteristic clear cells and growth patterns and may run additional tissue tests to separate clear cell cancer from other types, since the distinction changes treatment. The steps before that depend on the symptoms. A pelvic exam and imaging such as ultrasound, CT or MRI show where a mass is and whether it may have spread. CA-125, a blood marker often used in ovarian cancer, is less helpful here: it is raised in only about 57% of people with ovarian clear cell carcinoma, so a normal result does not rule this cancer out. Staging describes how far the cancer has spread, from stage I (confined to the organ where it started) to stage IV (spread to distant organs). For ovarian cancer, much of the staging is done during surgery, by removing and examining nearby tissue and lymph nodes. Clear cell cancers of the uterine lining are increasingly sorted by molecular testing of the tumor, for example for mismatch repair deficiency, a weakness in the tumor's ability to fix errors made when DNA is copied, which is linked to Lynch syndrome. These results help predict outlook and guide treatment and genetic testing.
Treatment depends on where the cancer started and its stage. Because clear cell cancer is uncommon, much of the evidence behind standard treatment comes from studies that mainly included other cancer types, which leaves real uncertainty in some decisions. For ovarian clear cell carcinoma, surgery is the foundation. It usually removes the uterus, both ovaries and fallopian tubes, and nearby tissue and lymph nodes to stage the cancer. In advanced disease, the aim is to remove all visible tumor, since leaving none behind is the strongest predictor of a good outcome. Platinum-based chemotherapy, commonly carboplatin with paclitaxel, generally follows. Clear cell cancer responds to these drugs less often than other ovarian cancers do, which is a large part of why advanced disease is hard to treat. For stage I disease, whether chemotherapy adds benefit is uncertain and major guidelines differ, so the decision rests on the exact substage and what surgery found. For some people with very early disease who want to keep the possibility of pregnancy, surgery that leaves the uterus and the other ovary in place may be discussed. Studies so far suggest similar survival, but they are small and some guidelines remain cautious. For clear cell cancer of the uterine lining, treatment usually starts with a hysterectomy (removal of the uterus) and staging, often followed by chemotherapy, radiation or both depending on stage and the tumor's molecular type. For advanced or recurrent disease, immunotherapy, which helps the immune system attack cancer, is now an approved option alongside chemotherapy: dostarlimab (Jemperli) is approved with carboplatin and paclitaxel for advanced or recurrent cancer of the uterine lining whatever the mismatch repair result, and tumors with mismatch repair deficiency tend to benefit most. Clear cell cancers of the cervix and vagina are treated with surgery, radiation therapy, chemotherapy or a combination, depending on size and location. If the cancer returns, options depend on how it responded before. Ovarian clear cell cancer that comes back after a long response to platinum chemotherapy may be treated with further surgery and platinum chemotherapy again; cancer that no longer responds is much harder to control, and treatment then focuses on slowing it and easing symptoms. For ovarian clear cell carcinoma, immunotherapy has given mixed results so far and is still being studied, mainly through clinical trials. Clinical trials are an important route to newer treatments for this uncommon cancer.
Outlook varies widely by site and stage. Ovarian clear cell carcinoma is usually found at stage I, and in recent studies about 9 in 10 people with stage I disease were alive five years later. Once the cancer has spread through the abdomen (stage III), survival is much lower, roughly half at five years in those studies. For clear cell cancer of the uterine lining, outlook depends heavily on the tumor's molecular type: some types do well, while the more common ones carry a higher risk of return. These figures describe groups and cannot predict any one person's course. Treatment usually means major surgery followed, for many people, by several months of chemotherapy given in cycles. Recovery from a hysterectomy takes about four to six weeks, depending on the type of surgery. Removing both ovaries before menopause brings on menopause symptoms, such as hot flashes, and ends fertility, which is worth discussing before surgery if it matters to you. After treatment, follow-up visits with exams, and sometimes blood tests and imaging, check for recurrence. People with Lynch syndrome or a strong family history may be offered genetic counseling, which can also guide screening for relatives.
See a clinician about bloating, pelvic or abdominal pain or pressure, or feeling full quickly that persists or gets worse, and about vaginal bleeding after menopause or bleeding or discharge not related to periods. If you know or suspect your mother took DES while pregnant with you, tell your clinician, since yearly checkups have generally been advised for DES daughters. Ovarian clear cell carcinoma carries a high risk of blood clots. Call your care team promptly for swelling, pain, warmth or redness in one leg, or for a fever during chemotherapy. After treatment, contact them between follow-up visits if bloating, pelvic or abdominal pain or vaginal bleeding returns. Sudden shortness of breath, chest pain that worsens with breathing, coughing up blood or fainting can mean a clot has reached the lungs; call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Clear Cell Adenocarcinoma is like, what's helped you, or ask the community a question.